GSK · story · 4 November
GSK · 7 headlines from 7 outlets, on 4 November 2026.
GSK and Alamar Biosciences are working together on a proteomic study involving 60,000 samples.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Yahoo Finance Singapore is the largest at 5.0, ahead of MarketScreener (5.0). Stock Titan is the smallest at 4.3.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Yahoo Finance Singapore | 5.0 |
| MarketScreener | 5.0 |
| TipRanks | 4.7 |
| Investing.com | 4.5 |
| StreetInsider | 4.5 |
| Investing.com India | 4.5 |
| Stock Titan | 4.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Yahoo Finance Singapore | 1 | +5.0 |
| MarketScreener | 1 | +5.0 |
| TipRanks | 1 | +4.7 |
| Investing.com | 1 | +4.5 |
| StreetInsider | 1 | +4.5 |
| Investing.com India | 1 | +4.5 |
| Stock Titan | 1 | +4.3 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +5.0 | Same collaboration framed as advancing personalised medicine |
| +5.0 | GSK is partner in a large research collaboration on disease biology |
| +4.7 | GSK named partner in sizeable biomarker research project |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science |
| +4.3 | Same collaboration covering several disease areas |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.